Drug Type CAR-T |
Synonyms TMMSTN02 |
Target |
Mechanism MSLN inhibitors(Mesothelin inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Tmunity Therapeutics, Inc.Startup |
Active Organization Tmunity Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | US | Tmunity Therapeutics, Inc.Startup | - |
Mesothelioma | Preclinical | US | Tmunity Therapeutics, Inc.Startup | - |
Ovarian Epithelial Carcinoma | Preclinical | US | Tmunity Therapeutics, Inc.Startup | - |
Pancreatic Cancer | Preclinical | US | Tmunity Therapeutics, Inc.Startup | - |